Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Evista TM
Active ingredients: raloxifene
What it is used for
Evista is indicated for the prevention and treatment of osteoporosis in post-menopausal women. Evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis. Evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 2 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White oval film coated tablet with 4165 printed in blue ink on one side
Images are the copyright of Medicines Information Pty Ltd
We are currently experiencing issues with Medicines Information data. Images displayed may not be current, please refer to the CMI.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on March 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient raloxifene
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Treatment – Bone Health
Treatment Diagnosed osteoporosis requires prescribed treatment to protect bone health
Read more on Healthy Bones Australia website
Osteoporosis Treatment and Bone Health
Diagnosed osteoporosis requires prescribed treatment to protect bone health.
Read more on Healthy Bones Australia website
Vaginal health after breast cancer: A guide for patients - Australasian Menopause Society
Women who have had breast cancer treatment before menopause might find they develop symptoms such as hot flushes, night sweats, joint aches and vaginal dryness. These are symptoms of low oestrogen, which occur naturally with age, but may also occur in younger women undergoing treatment for breast cancer. These changes are called the genito-urinary syndrome of menopause (GSM), which was previously known as atrophic vaginitis.
Read more on Australasian Menopause Society website
Osteoporosis treatment options - MyDr.com.au
Osteoporosis treatment choices (including medicines and lifestyle measures) are based on your age, sex, general health, the severity of your osteoporosis and the likelihood of you breaking a bone.
Read more on myDr website
Top results
Osteoporosis - Australasian Menopause Society
Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during a woman’s 20s to 30s when the skeleton has stopped growing and bones are at their strongest. The female sex hormone oestrogen plays an important role in maintaining bone strength. After menopause oestrogen levels drop and this may result in increased bone loss. The average woman loses up to 10 per cent of
Read more on Australasian Menopause Society website